Profile data is unavailable for this security.
About the company
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
- Revenue in JPY (TTM)26.70bn
- Net income in JPY5.50bn
- Incorporated1973
- Employees1.21k
- LocationShin Nippon Biomedical Laboratories Ltd28F, St Luke's Tower, 8-1, Akashi-choCHUO-KU 104-0044JapanJPN
- Phone+81 355655001
- Fax+81 355656160
- Websitehttps://www.snbl.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Koa Shoji Holdings Co Ltd | 22.27bn | 2.86bn | 33.48bn | 297.00 | 11.72 | 1.52 | 9.40 | 1.50 | 72.09 | 72.09 | 562.08 | 554.93 | 0.7777 | 5.99 | 2.42 | 74,979,020.00 | 9.97 | 7.91 | 12.38 | 9.93 | 30.12 | 28.74 | 12.83 | 10.48 | 3.69 | 29.24 | 0.1197 | 19.64 | 8.35 | 8.27 | 13.90 | 29.60 | -21.26 | 15.52 |
| Fuji Pharma Co Ltd | 41.64bn | 5.06bn | 39.36bn | 1.62k | 7.64 | 0.9208 | 4.79 | 0.9452 | 208.19 | 208.19 | 1,713.27 | 1,726.70 | 0.5039 | 1.40 | 2.82 | 25,687,230.00 | 6.12 | 4.10 | 8.90 | 5.58 | 38.51 | 42.41 | 12.15 | 7.55 | 0.7165 | -- | 0.3947 | 31.17 | 15.42 | 1.52 | 27.41 | 0.3709 | 19.04 | 5.73 |
| Daito Pharmaceutical Co Ltd | 45.19bn | 3.28bn | 39.64bn | 1.01k | 12.15 | 0.7624 | 5.83 | 0.8771 | 207.85 | 207.85 | 2,864.81 | 3,311.81 | 0.6193 | 1.81 | 2.65 | 44,701,280.00 | 4.35 | 6.99 | 5.64 | 9.29 | 21.38 | 22.71 | 7.03 | 8.83 | 1.15 | -- | 0.1231 | 17.08 | 3.77 | 2.49 | -22.88 | 3.43 | 7.48 | 12.70 |
| Seikagaku Corp | 34.68bn | 1.31bn | 42.27bn | 976.00 | 31.00 | 0.566 | 14.61 | 1.22 | 24.00 | 24.00 | 635.69 | 1,314.47 | 0.4431 | 1.75 | 4.31 | 35,530,740.00 | 1.67 | 0.438 | 1.80 | 0.4797 | 50.52 | 55.91 | 3.77 | 1.07 | 5.44 | -- | 0.0055 | 452.20 | -4.00 | 2.09 | -40.10 | -10.63 | 8.40 | 0.00 |
| Shin Nippon Biomedical Laboratories Ltd | 26.70bn | 5.50bn | 64.20bn | 1.21k | 11.67 | 2.13 | 8.81 | 2.40 | 132.18 | 132.18 | 641.45 | 725.03 | 0.4107 | 1.27 | 5.55 | 22,105,960.00 | 8.46 | 9.47 | 12.30 | 14.34 | 52.19 | 50.00 | 20.60 | 24.39 | 0.9618 | -- | 0.4687 | 23.01 | 41.37 | 8.61 | -14.98 | -- | 37.23 | -- |
| Katakura Industries Co., Ltd. | 39.97bn | 3.05bn | 67.96bn | 1.04k | 21.01 | 0.8526 | 11.54 | 1.70 | 91.86 | 91.86 | 1,206.19 | 2,263.56 | 0.2879 | 2.26 | 4.70 | 38,434,620.00 | 2.33 | 2.35 | 3.05 | 3.34 | 38.45 | 37.75 | 8.09 | 8.32 | 2.57 | -- | 0.1236 | 18.81 | 16.62 | -2.04 | 8.09 | 18.87 | -7.46 | 10.76 |
| ispace Inc | 1.99bn | -2.52bn | 70.87bn | 216.00 | -- | 17.08 | -- | 35.59 | -33.88 | -33.88 | 24.76 | 44.55 | 0.1476 | -- | 24.87 | 9,219,852.00 | -18.66 | -- | -32.11 | -- | 46.91 | -- | -126.42 | -- | 1.72 | -16.56 | 0.7317 | -- | 46.74 | -- | -180.75 | -- | -- | -- |
| ASKA Pharmaceutical Holdings Co Ltd | 62.03bn | 6.51bn | 71.18bn | 747.00 | 10.12 | 1.09 | 7.56 | 1.15 | 230.05 | 230.05 | 2,191.75 | 2,131.76 | 0.6682 | 1.72 | 3.40 | 83,033,460.00 | 7.02 | 3.37 | 9.09 | 4.25 | 48.12 | 45.39 | 10.50 | 5.02 | 1.96 | -- | 0.1433 | 15.79 | 6.81 | 4.32 | -1.21 | 12.16 | -13.15 | 2.71 |
| Eiken Chemical Co Ltd | 39.90bn | 2.95bn | 77.28bn | 754.00 | 25.44 | 1.48 | 14.75 | 1.94 | 78.83 | 78.83 | 1,067.99 | 1,355.09 | 0.6013 | 2.74 | 3.07 | 52,923,080.00 | 4.44 | 8.83 | 5.45 | 11.34 | 42.67 | 46.39 | 7.38 | 12.16 | 2.95 | -- | 0.0563 | 31.24 | 0.6396 | 4.34 | -7.75 | 17.07 | 0.6216 | 15.33 |
Data as of May 02 2024. Currency figures normalised to Shin Nippon Biomedical Laboratories Ltd's reporting currency: Japanese Yen JPY
14.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Asset Management One Co., Ltd.as of 31 May 2023 | 1.64m | 3.93% |
| Sumitomo Mitsui DS Asset Management Co., Ltd.as of 04 Apr 2024 | 828.00k | 1.99% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 671.50k | 1.61% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 578.10k | 1.39% |
| Nomura Asset Management Co., Ltd.as of 29 Mar 2024 | 568.50k | 1.37% |
| Goldman Sachs Asset Management Co., Ltd. (Japan)as of 31 Jan 2024 | 405.10k | 0.97% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 352.00k | 0.85% |
| Daiwa Asset Management Co. Ltd.as of 29 Mar 2024 | 348.90k | 0.84% |
| Nikko Asset Management Co., Ltd.as of 05 Apr 2024 | 282.70k | 0.68% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 278.70k | 0.67% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
